

Information For the User  
Atorvastatin (40mg) + Ezetimibe (10mg) Tablet

# Atorable EZ 40 Tablet

**Brand Name:** Atorable EZ 40 Tablet

**Dosage Form:** Tablet

**Composition:**

Each film-coated tablet contains:

- Atorvastatin Calcium IP equivalent to Atorvastatin 40 mg
- Ezetimibe IP 10 mg

**Description:**

Atorable EZ 40 Tablet is a combination of Atorvastatin, a HMG-CoA reductase inhibitor, and Ezetimibe, a cholesterol absorption inhibitor. This formulation is indicated for the management of dyslipidemia in patients requiring intensive lipid-lowering therapy. It helps in reducing elevated levels of total cholesterol, LDL-cholesterol, and triglycerides, thereby lowering the risk of atherosclerotic cardiovascular disease.

**Indications:**

Indicated for the treatment of:

- Primary hypercholesterolemia
- Mixed dyslipidemia
- Hyperlipidemia in patients inadequately controlled with statin monotherapy

It helps in improving lipid parameters and reducing cardiovascular risk.

**Dosage & Administration:**

Dosage should be as directed by the physician.

The tablet should be swallowed whole with water and may be taken with or without food.

Periodic monitoring of lipid profile and liver function tests is recommended.

**Pharmacological Action:**

Atorvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing LDL receptor expression, while Ezetimibe selectively inhibits intestinal cholesterol absorption. The combination provides an additive and complementary lipid-lowering effect.

**Side Effects:**

Generally well tolerated.

Possible side effects include headache, myalgia, gastrointestinal discomfort, nausea, and elevation of hepatic enzymes.

**Precautions & Warnings:**

- Use with caution in patients with hepatic impairment
- Monitor liver enzymes before initiation and periodically thereafter
- Discontinue therapy if unexplained muscle pain, tenderness, or weakness occurs
- Contraindicated during pregnancy and lactation

**Drug Interactions:**

Caution is advised when used with other lipid-lowering agents due to increased risk of myopathy.

Concomitant use with strong CYP3A4 inhibitors may increase atorvastatin plasma levels.

**Storage:**

Store below 25°C in a cool, dry place.

Protect from light and moisture.

Keep out of reach of children.

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for